



CLN8 (T-20): sc-49639

BACKGROUND

CLN8, a 286 amino acid transmembrane protein, localizes mainly to the endoplasmic reticulum, but also partially to the ER-Golgi intermediate compartment (ERGIC). Mutations in the CLN8 gene cause neuronal ceroid lipofuscinosis 8 and progressive epilepsy with mental retardation (EPMR). Both disorders are forms of neuronal ceroid-lipofuscinose (NCL), a group of progressive neurodegenerative diseases found in children, characterized by failure of psychomotor development, impaired vision, seizures and premature death. The CLN8 protein is one of eight proteins in the CLN family, including CLN1-CLN7, which are associated with NCL.

REFERENCES

1. Online Mendelian Inheritance in Man, OMIM™. 2002. Johns Hopkins University, Baltimore, MD. MIM Number: 607837. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>
2. Tynnela, J., et al. 2004. Hippocampal pathology in the human neuronal ceroid-lipofuscinoses: distinct patterns of storage deposition, neurodegeneration and glial activation. *Brain Pathol.* 14: 349-357.
3. Mole, SE., et al. 2005. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. *Neurogenetics* 6: 107-126.
4. Wendt, KD., et al. 2005. Behavioral assessment in mouse models of neuronal ceroid lipofuscinosis using a light-cued T-maze. *Behav. Brain Res.* 161: 175-182.
5. Lonka, L., et al. 2005. The neuronal ceroid lipofuscinosis CLN8 gene expression is developmentally regulated in mouse brain and upregulated in the hippocampal kindling model of epilepsy. *BMC Neurosci.* 6: 27.
6. Katz, M.L., et al. 2005. A mutation in the CLN8 gene in English Setter dogs with neuronal ceroid-lipofuscinosis. *Biochem. Biophys. Res. Commun.* 327: 541-547.
7. Hermansson, M. et al. 2005. Mass spectrometric analysis reveals changes in phospholipid, neutral sphingolipid and sulfatide molecular species in progressive epilepsy with mental retardation, EPMR, brain: a case study. *J. Neurochem.* 95: 609-617.

CHROMOSOMAL LOCATION

Genetic locus: CLN8 (human) mapping to 8p23; Cln8 (mouse) mapping to 8 A1.1.

SOURCE

CLN8 (T-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the N-terminus of CLN8 of mouse origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-49639 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

CLN8 (T-20) is recommended for detection of CLN8 of mouse and rat origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

Suitable for use as control antibody for CLN8 siRNA (m): sc-60412.

Molecular Weight of CLN8: 33 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.